Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as Ozem­pic'

No­vo Nordisk’s pri­or­i­ty re­view vouch­er on oral semaglu­tide has paid off. The FDA ap­proval for the GLP-1 drug hit late Fri­day morn­ing, around six months af­ter the NDA fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.